Clinical Trial Update: A Safety & Efficacy Study of Treatment With AP1189 in Rheumatoid Arthritis Patients naïve to DMARD Treatment [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for AP1189 in DMARD-naïve rheumatoid arthritis patients completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• AP1189

Snippet

Sponsor: SynAct Pharma Aps | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED